Jefferies upgrades Recordati stock to Buy on rare disease momentum

Jefferies upgraded Recordati (BIT:RECI) to Buy from Hold, raising its price target to EUR61.50, citing a significant valuation discrepancy where the current share price implies a 2024-2027 revenue CAGR of -1% to +2% versus the company's guidance of +9% to +11%. The firm anticipates growth driven by Recordati's Rare Diseases segment, particularly Enjaymo and Isturisa, alongside improving margin visibility and top-line momentum. Jefferies also highlighted the company's M&A strategy, estimating EUR450 million in annual spending to achieve its 2030 revenue doubling goal, noting the recent Vazkepa deal reduces future M&A requirements.

Analysis

Jefferies has upgraded Recordati SpA (BIT:RECI) to a 'Buy' rating from 'Hold', increasing its price target to EUR61.50 from EUR55.00. The core of the upgrade thesis rests on a significant valuation disconnect; Jefferies' analysis indicates the current stock price implies a revenue Compound Annual Growth Rate (CAGR) between -1% and +2% for the 2024-2027 period, which is substantially below the company's own guidance of +9% to +11%. Growth momentum is expected to be fueled by the company's Rare Diseases segment, with specific products Enjaymo and Isturisa highlighted as key drivers. The positive outlook is further supported by improving margin visibility and top-line momentum. Mergers and acquisitions remain a central pillar of Recordati's long-term strategy, which aims to double 2024 revenues by 2030. Jefferies estimates this will require approximately EUR450 million in annual M&A spending, noting that the recent acquisition of Vazkepa has already partially de-risked this strategy by reducing the forward M&A requirement.

Key Decisions for Investors

• Investors should consider the significant valuation gap identified by Jefferies, as the primary investment thesis hinges on the market re-rating the stock closer to the company's own +9% to +11% revenue growth guidance.
• Monitor sales performance within the Rare Diseases segment, particularly for key products Enjaymo and Isturisa, as their success is cited as a critical driver for achieving near-term growth targets.
• Track the company's execution on its M&A strategy, as the ability to deploy an estimated EUR450 million annually in value-accretive deals is essential for meeting the 2030 revenue doubling objective.